PACB PACIFIC BIOSCIENCES CALIF IN revenue, earnings and financials
For the quarter ended June 30, 2026, PACIFIC BIOSCIENCES CALIF IN reported revenue of $39.0M (down 1.9% from a year earlier), net income of −$44.7M and diluted EPS of −$0.14; over the last four quarters revenue was $159M and net income −$131M; for the fiscal year ended December 2025 revenue was $160M, up 3.9% on the year before.
PACB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $160M, gross profit $45.8M, operating income −$554M, net income −$546M (margin -341.5%), EPS −$1.82
- Fiscal year ended Dec 2024: revenue $154M, gross profit $37.3M, operating income −$474M, net income −$310M (margin -201.2%), EPS −$1.59
- Fiscal year ended Dec 2023: revenue $201M, gross profit $52.8M, operating income −$334M, net income −$307M (margin -153.0%), EPS −$1.21
- Fiscal year ended Dec 2022: revenue $128M, gross profit $49.0M, operating income −$307M, net income −$314M (margin -244.9%), EPS −$1.40
- Fiscal year ended Dec 2021: revenue $131M, gross profit $58.9M, operating income −$210M, net income −$181M (margin -138.8%), EPS −$0.89
PACB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $39.0M (down 1.9% year over year), net income −$44.7M, EPS −$0.14
- Quarter ended Mar 31, 2026: revenue $37.2M (up 0.1% year over year), net income −$8.28M, EPS −$0.03
- Quarter ended Dec 31, 2025 (from the annual report): revenue $44.6M (up 13.8% year over year), net income −$40.4M, EPS −$0.11
- Quarter ended Sep 30, 2025: revenue $38.4M (down 3.8% year over year), net income −$38.0M, EPS −$0.13
- Quarter ended Jun 30, 2025: revenue $39.8M (up 10.4% year over year), net income −$41.9M, EPS −$0.14
- Quarter ended Mar 31, 2025: revenue $37.2M (down 4.3% year over year), net income −$426M, EPS −$1.44
- Quarter ended Dec 31, 2024 (from the annual report): revenue $39.2M (down 32.8% year over year), net income $2.32M, EPS −$0.44
- Quarter ended Sep 30, 2024: revenue $40.0M (down 28.2% year over year), net income −$60.7M, EPS −$0.22
- Quarter ended Jun 30, 2024: revenue $36.0M (down 24.3% year over year), net income −$173M, EPS −$0.64
- Quarter ended Mar 31, 2024: revenue $38.8M (down 0.2% year over year), net income −$78.2M, EPS −$0.29
- Quarter ended Dec 31, 2023 (from the annual report): revenue $58.4M (up 113.3% year over year), net income −$82.0M, EPS −$0.31
- Quarter ended Sep 30, 2023: revenue $55.7M (up 72.4% year over year), net income −$66.9M, EPS −$0.26
- Quarter ended Jun 30, 2023: revenue $47.6M (up 34.1% year over year), net income −$69.8M, EPS −$0.28
- Quarter ended Mar 31, 2023: revenue $38.9M (up 17.3% year over year), net income −$88.0M, EPS −$0.36
- Quarter ended Dec 31, 2022 (from the annual report): revenue $27.4M (down 24.1% year over year), net income −$84.3M, EPS −$0.37
- Quarter ended Sep 30, 2022: revenue $32.3M (down 7.4% year over year), net income −$77.0M, EPS −$0.34
- Quarter ended Jun 30, 2022: revenue $35.5M (up 15.9% year over year), net income −$71.4M, EPS −$0.32
- Quarter ended Mar 31, 2022: revenue $33.2M (up 14.4% year over year), net income −$81.5M, EPS −$0.37
- Quarter ended Dec 31, 2021 (from the annual report): revenue $36.0M, net income −$69.3M, EPS −$0.31
- Quarter ended Sep 30, 2021: revenue $34.9M, net income $16.5M, EPS $0.08
PACB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$111M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2024: operating cash flow −$206M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow −$259M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2022: operating cash flow −$263M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2021: operating cash flow −$111M, share buybacks n/a, dividends $0.00 per share
PACB balance sheet
- Jun 30, 2026: cash $61.0M, total assets $752M, total liabilities $785M, shareholders' equity −$33.2M
- Mar 31, 2026: cash $56.3M, total assets $782M, total liabilities $780M, shareholders' equity $2.37M
- Dec 31, 2025: cash $63.7M, total assets $784M, total liabilities $779M, shareholders' equity $5.35M
- Sep 30, 2025: cash $56.5M, total assets $803M, total liabilities $767M, shareholders' equity $36.1M
- Jun 30, 2025: cash $54.8M, total assets $825M, total liabilities $764M, shareholders' equity $61.5M
- Mar 31, 2025: cash $58.5M, total assets $861M, total liabilities $769M, shareholders' equity $91.6M
- Dec 31, 2024: cash $55.4M, total assets $1.26B, total liabilities $754M, shareholders' equity $507M
- Sep 30, 2024: cash $78.0M, total assets $1.45B, total liabilities $997M, shareholders' equity $453M
What is PACB's revenue?
PACIFIC BIOSCIENCES CALIF IN reported $159M of revenue over its last four quarters, through June 30, 2026.
Is PACB profitable?
No. PACIFIC BIOSCIENCES CALIF IN lost $131M over the last four quarters.
What is PACB's EPS?
Diluted earnings per share over the last four quarters were −$0.41; −$0.14 in the latest quarter.